Madrigal Pharmaceuticals(MDGL) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates • Third-quarter 2024 net sales of $62.2 million • Rezdif ra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdif ra-covered lives require biopsy • Completed enrollment of clinical outcomes study of Rezdif ra in patients with compensated NASH/MASH cirrhosis • Reports cash, cash equivalents, restricted cash and marketable ...